

## NOVEMBER 2025

Date	Headline and Source	Link	Summary
4 <sup>th</sup> November	AstraZeneca Gets SEC Nod to Update Lokelma Prescribing Information for Hyperkalemia Treatment Medical Dialogues, November 04, 2025	<a href="#">AstraZeneca Gets SEC Nod to Update Lokelma Prescribing Information for Hyperkalemia Treatment</a>	Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent.
6 <sup>th</sup> November	CDSCO Panel Approves Updated Package Insert for Takeda's Vedolizumab Medical Dialogues, November 06, 2025	<a href="#">CDSCO Panel Approves Updated Package Insert for Takeda's Vedolizumab</a>	In a key regulatory development, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has approved the updated package insert for Vedolizumab 300 mg and 108 mg powder for concentrate for solution for infusion, marketed by Takeda Biopharmaceuticals India.
7 <sup>th</sup> November	Bayer secures expanded approval for Kerendia in India for heart failure treatment ET Pharma, November 07, 2025	<a href="#">Bayer secures expanded approval for Kerendia in India for heart failure treatment</a>	German pharmaceutical giant Bayer has secured expanded approval for its innovative therapy Kerendia for treating adult patients with heart failure. Kerendia, developed from the active ingredient Finerenone, is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) that blocks MR overactivation a key driver of inflammation and fibrosis in both the heart and the kidney.
9 <sup>th</sup> November	Bayer's chronic kidney disease therapy Kerendia gets additional approval as heart failure drug too in India Fortune, November 09, 2025	<a href="#">Bayer's chronic kidney disease therapy Kerendia gets additional approval as heart failure drug too in India</a>	Together with its role in chronic kidney disease linked to type 2 diabetes, finerenone represents Bayer's innovation against India's most pressing health burdens such as cardiovascular disease and chronic kidney disease, strengthening our commitment to reimagining cardiovascular care and improving patient outcomes in the country Shweta Rai, Managing Director India and Country Division Head South Asia, Bayer's Pharmaceutical Division, said.
9 <sup>th</sup> November	Mounjaro Tops India's Drug Market   Weight-Loss Boom, Big Pharma Battle Ahead Business Today, November 09, 2025	<a href="#">Mounjaro Tops India's Drug Market   Weight-Loss Boom, Big Pharma Battle Ahead</a>	Eli Lilly's Mounjaro has shot to the No 1 spot, recording Rs 100 crore in sales in October alone and over Rs 333 crore since its launch in March. The therapy, used for diabetes and obesity management, has sparked a new race in the pharma space.

11 <sup>th</sup> November	Novo Nordisk partners Emcure Pharma for weight loss medicine Poviztra in India The Financial Express, November 11, 2025	<a href="#">Novo Nordisk partners Emcure Pharma for weight loss medicine Poviztra in India</a>	Novo Nordisk India has partnered with Emcure Pharma to commercialise weight loss drug Poviztra in India, which will serve as a second brand of Wegovy. Emcure Pharma is the first Indian company to receive exclusive rights to distribute and commercialise Poviztra, a semaglutide injection of 2.4 mg for weight loss.
12 <sup>th</sup> November	Sanofi's Tetraxim Vaccine Gets CDSCO Panel Nod for Expanded Indication Medical Dialogues, November 12, 2025	<a href="#">Sanofi's Tetraxim Vaccine Gets CDSCO Panel Nod for Expanded Indication</a>	The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organization (CDSCO), has approved an additional indication for Sanofi Healthcare India's combination vaccine, Adsorbed Diphtheria, Tetanus, Pertussis (Acellular Component) and Inactivated Poliomyelitis Vaccine, in line with the EU SmPC, excluding the statement that Tetraxim can be used to reconstitute the Haemophilus influenzae type b conjugate vaccine (ActHib).
14 <sup>th</sup> November	PRASHO and Pfizer Collaborate to Enhance Migraine Awareness with Corporate Workshops Across Hyderabad Workplaces The Hans India, November 14, 2025	<a href="#">PRASHO and Pfizer Collaborate to Enhance Migraine Awareness with Corporate Workshops Across Hyderabad Workplaces</a>	To address one of the most underestimated public health challenges impacting India's workforce productivity, the Pragyaan Sustainable Health Outcomes Foundation (PRASHO), in collaboration with Pfizer, one of the world's premier innovative biopharmaceutical companies, has launched a series of Migraine Awareness and Workplace Productivity workshops to be conducted across corporate organisations in Hyderabad over the coming weeks.
14 <sup>th</sup> November	Expect further innovation in cancer therapies: AstraZeneca Pharma India's Praveen Rao Akkinapally Business Today, November 14, 2025	<a href="#">Expect further innovation in cancer therapies: AstraZeneca Pharma India's Praveen Rao Akkinapally</a>	Global biopharmaceutical company AstraZeneca is strengthening focus on areas such as oncology, cardiovascular, renal, rare diseases, and the emerging GLP1 segment. In September, it announced its third tranche of investment in the country over the past two years.
18 <sup>th</sup> November	Pfizer launches gene-related peptide for migraine in India The Economic Times, November 18, 2025	<a href="#">Pfizer launches gene-related peptide for migraine in India</a>	Pfizer India arm has announced the launch of calcitonin gene-related peptide (CGRP) receptor antagonist: Rimegepant for acute treatment of migraine, in adults with a previous insufficient response to triptan. Rimegepant is designed to target migraine's pathophysiology calcitonin gene-related peptide (CGRP) and delivers rapid and sustained pain relief lasting up to 48 hours posttreatment, while not

			associated with the risk of medication overuse headaches.
18 <sup>th</sup> November	AstraZeneca partners with Sun Pharma to expand access to hyperkalaemia treatment Lokelma Money Control, November 18, 2025	<a href="#">AstraZeneca partners with Sun Pharma to expand access to hyperkalaemia treatment Lokelma</a>	AstraZeneca Pharma India on Monday said it has partnered with India's largest drugmaker Sun Pharmaceutical Industries to comarket Sodium Zirconium Cyclosilicate (SZC), a therapy for hyperkalaemia, in a bid to widen access to treatment for patients with chronic kidney disease and heart failure.
19 <sup>th</sup> November	Alzheimer's drug: Eli Lilly get nod from CDSCO for it Alzheimer's drug Donanemab The Economic Times, November 19, 2025	<a href="#">Alzheimer's drug: Eli Lilly get nod from CDSCO for it Alzheimer's drug Donanemab</a>	Eli Lilly has secured marketing authorization from India's CDSCO for its Alzheimer's drug, donanemab. This new disease-modifying therapy targets amyloid plaques, offering a significant milestone in addressing the urgent needs of early-stage Alzheimer's patients in India. The drug aims to slow cognitive decline, providing more time and improved quality of life for individuals and their families.
19 <sup>th</sup> November	Pfizer launches Rimegepant ODT: Breakthrough migraine treatment now available in India The Telegraph, November 19, 2025	<a href="#">Pfizer launches Rimegepant ODT: Breakthrough migraine treatment now available in India</a>	Drug maker Pfizer on Monday said it has launched a new medication for migraine treatment. The company has introduced Rimegepant ODT in India for adults with a previous insufficient response to triptan, the usual drugs for treating migraine.
20 <sup>th</sup> November	Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow Tucker The Economic Times, November 20, 2025	<a href="#">Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow Tucker</a>	Having a really good product, partnering with others in the ecosystem, and supporting education for patients, will allow us to be part of making a big dent in this obesity and type 2 diabetes health concerns for India, Winselow Tucker, president and general manager of Eli Lilly and Company (India), told ET.
20 <sup>th</sup> November	Pfizer Launches New Rimegepant Oral Medication in India for Rapid Migraine Relief and Acute Treatment The Hans India, November 20, 2025	<a href="#">Pfizer Launches New Rimegepant Oral Medication in India for Rapid Migraine Relief and Acute Treatment</a>	Meenakshi Nevatia, Managing Director, Pfizer Ltd, India, said, We are excited to bring Rimegepant to India Its potential impact on people living with migraine will be tremendous We believe this treatment will help people with migraine manage pain more effectively and reclaim productive days sooner than with currently available options.
20 <sup>th</sup> November	AstraZeneca strengthens COPD treatment pathways Express Pharma, November 20, 2025	<a href="#">AstraZeneca strengthens COPD treatment pathways</a>	AstraZeneca India, a science-led biopharmaceutical company, is advancing its commitment to chronic respiratory care by extending its successful Centre of Excellence (COE) concept. This concept originally developed for severe asthma, to the management of Chronic Obstructive Pulmonary Disease (COPD).

21 <sup>st</sup> November	PRASHO and Pfizer collaborate to enhance migraine awareness with corporate workshops across Hyderabad PharmaBiz, November 21, 2025	<a href="#">PRASHO and Pfizer collaborate to enhance migraine awareness with corporate workshops across Hyderabad</a>	To address one of the most underestimated public health challenges impacting India's workforce productivity, the Pragyaan Sustainable Health Outcomes Foundation (PRASHO), in collaboration with Pfizer, one of the world's premier innovative biopharmaceutical companies, has launched a series of migraine awareness and workplace productivity workshops to be conducted across corporate organisations in Hyderabad over the coming weeks.
25 <sup>th</sup> November	AI-Enabled Lung Nodule Clinic Launched to Boost Early Lung Cancer Detection The Economic Times, November 25, 2025	<a href="#">AI-Enabled Lung Nodule Clinic Launched to Boost Early Lung Cancer Detection</a>	Yashoda Hospital, Hitech City, in collaboration with Qure.ai and AstraZeneca, has launched an Artificial Intelligence (AI) powered lung nodule clinic to strengthen early detection and timely management of lung cancer and other major lung diseases. The initiative embeds AI across the entire imaging-to-care pathway, critical at a time when India still lacks a national lung cancer screening programme.
30 <sup>th</sup> November	Sanofi Gets CDSCO Panel Nod to Update Prescribing Information for Xenpozyme Medical Dialogues, November 30, 2025	<a href="#">Sanofi Gets CDSCO Panel Nod to Update Prescribing Information for Xenpozyme</a>	The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO), has recommended approval for updating the Prescribing Information of Xenpozyme (Olipudase alfa Powder for concentrate for solution for infusion 20 mg vial), manufactured by Sanofi Healthcare India.

-----